Potential roles of mesenchymal stromal cells in islet allo‐ and xenotransplantation for type 1 diabetes mellitus

2021 ◽  
Author(s):  
Zepeng Qu ◽  
Qi Lou ◽  
David K. C. Cooper ◽  
Zuhui Pu ◽  
Ying Lu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells

scholarly journals Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro

2016 ◽  
Vol 5 (11) ◽  
pp. 1485-1495 ◽  
Author(s):  
Lindsay C. Davies ◽  
Jessica J. Alm ◽  
Nina Heldring ◽  
Guido Moll ◽  
Caroline Gavin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Healthy Controls

scholarly journals Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus

2019 ◽  
Vol 8 (2) ◽  
pp. 249 ◽  
Author(s):  
Hiroyuki Takahashi ◽  
Naoaki Sakata ◽  
Gumpei Yoshimatsu ◽  
Suguru Hasegawa ◽  
Shohta Kodama
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Adipose Tissue ◽  
Insulin Therapy ◽  
Type 1 Diabetes Mellitus ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Cellular Therapy ◽  
Therapeutic Benefits

Type 1 diabetes mellitus (T1DM) is caused by the autoimmune targeting of pancreatic β-cells, and, in the advanced stage, severe hypoinsulinemia due to islet destruction. In patients with T1DM, continuous exogenous insulin therapy cannot be avoided. However, an insufficient dose of insulin easily induces extreme hyperglycemia or diabetic ketoacidosis, and intensive insulin therapy may cause hypoglycemic symptoms including hypoglycemic shock. While these insulin therapies are efficacious in most patients, some additional therapies are warranted to support the control of blood glucose levels and reduce the risk of hypoglycemia in patients who respond poorly despite receiving appropriate treatment. There has been a recent gain in the popularity of cellular therapies using mesenchymal stromal cells (MSCs) in various clinical fields, owing to their multipotentiality, capacity for self-renewal, and regenerative and immunomodulatory potential. In particular, adipose tissue-derived MSCs (ADMSCs) have become a focus in the clinical setting due to the abundance and easy isolation of these cells. In this review, we outline the possible therapeutic benefits of ADMSC for the treatment of T1DM.

Effects of mesenchymal stromal cells on type 1 diabetes mellitus rat muscles

2018 ◽  
Vol 58 (4) ◽  
pp. 583-591 ◽  
Author(s):  
Maria Augusta Sabadine ◽  
Thiago Luiz Russo ◽  
Genoveva Flores Luna ◽  
Angela Merice Oliveira Leal
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells

scholarly journals Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Juliana Navarro Ueda Yaochite ◽  
Kalil Willian Alves de Lima ◽  
Carolina Caliari-Oliveira ◽  
Patricia Vianna Bonini Palma ◽  
Carlos Eduardo Barra Couri ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Stromal Cells ◽  
Multipotent Mesenchymal Stromal Cells ◽  
Newly Diagnosed ◽  
Immunomodulatory Properties
Sign in / Sign up

Export Citation Format

Share Document